학술논문
Serum Uric Acid Predicts All-Cause and Cardiovascular Mortality Independently of Hypertriglyceridemia in Cardiometabolic Patients without Established CV Disease: A Sub-Analysis of the URic acid Right for heArt Health (URRAH) Study
Document Type
article
Author
Alessandro Mengozzi; Nicola Riccardo Pugliese; Giovambattista Desideri; Stefano Masi; Fabio Angeli; Carlo Maria Barbagallo; Michele Bombelli; Federica Cappelli; Edoardo Casiglia; Rosario Cianci; Michele Ciccarelli; Arrigo F. G. Cicero; Massimo Cirillo; Pietro Cirillo; Raffaella Dell’Oro; Lanfranco D’Elia; Claudio Ferri; Ferruccio Galletti; Loreto Gesualdo; Cristina Giannattasio; Guido Grassi; Guido Iaccarino; Luciano Lippa; Francesca Mallamaci; Alessandro Maloberti; Maria Masulli; Alberto Mazza; Maria Lorenza Muiesan; Pietro Nazzaro; Paolo Palatini; Gianfranco Parati; Roberto Pontremoli; Fosca Quarti-Trevano; Marcello Rattazzi; Gianpaolo Reboldi; Giulia Rivasi; Elisa Russo; Massimo Salvetti; Valerie Tikhonoff; Giuliano Tocci; Andrea Ungar; Paolo Verdecchia; Francesca Viazzi; Massimo Volpe; Claudio Borghi; Agostino Virdis
Source
Metabolites, Vol 13, Iss 2, p 244 (2023)
Subject
Language
English
ISSN
2218-1989
Abstract
High serum uric acid (SUA) and triglyceride (TG) levels might promote high-cardiovascular risk phenotypes across the cardiometabolic spectrum. However, SUA predictive power in the presence of normal and high TG levels has never been investigated. We included 8124 patients from the URic acid Right for heArt Health (URRAH) study cohort who were followed for over 20 years and had no established cardiovascular disease or uncontrolled metabolic disease. All-cause mortality (ACM) and cardiovascular mortality (CVM) were explored by the Kaplan–Meier estimator and Cox multivariable regression, adopting recently defined SUA cut-offs for ACM (≥4.7 mg/dL) and CVM (≥5.6 mg/dL). Exploratory analysis across cardiometabolic subgroups and a sensitivity analysis using SUA/serum creatinine were performed as validation. SUA predicted ACM (HR 1.25 [1.12–1.40], p < 0.001) and CVM (1.31 [1.11–1.74], p < 0.001) in the whole study population, and according to TG strata: ACM in normotriglyceridemia (HR 1.26 [1.12–1.43], p < 0.001) and hypertriglyceridemia (1.31 [1.02–1.68], p = 0.033), and CVM in normotriglyceridemia (HR 1.46 [1.23–1.73], p < 0.001) and hypertriglyceridemia (HR 1.31 [0.99–1.64], p = 0.060). Exploratory and sensitivity analyses confirmed our findings, suggesting a substantial role of SUA in normotriglyceridemia and hypertriglyceridemia. In conclusion, we report that SUA can predict ACM and CVM in cardiometabolic patients without established cardiovascular disease, independent of TG levels.